Drug intelligence / Profile preview

PTNR-TM 006

Development stage: Preclinical
Lead developer: Vivera Pharmaceuticals
Modality: Small Molecules
Administration: Sublingual

Overview

PTNR-TM 006 is a preclinical-stage drug candidate being developed by Vivera Biosciences (a division of Vivera Pharmaceuticals) in collaboration with an undisclosed third-party partner. The candidate is designed for the treatment of central nervous system (CNS) disorders. It utilizes Vivera's proprietary, patented **TABMELT** sublingual drug delivery system, which is designed to allow rapid absorption of the active pharmaceutical ingredient directly into the bloodstream through the sublingual mucosa, bypassing the gastrointestinal tract and hepatic first-pass metabolism. The specific active ingredient and biological target of PTNR-TM 006 remain proprietary and have not been publicly disclosed.

Other names: PTNR – TM 006

Beyond the preview

Go deeper on PTNR-TM 006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTNR-TM 006.

Explore the full profile